Early treatment does delay MS disease progression, new study confirms

Early treatment with disease modifying therapies (DMTs) is most effective in preventing progression of multiple sclerosis, according to a large-scale Danish study. The study “Early versus Later Treatment Start in Multiple Sclerosis – A Register Based Cohort Study” is to be presented at the 2018 Annual Meeting of the American Academy of Neurology (AAN). This … Continue reading Early treatment does delay MS disease progression, new study confirms

MS therapy alemtuzumab is named a ‘rip-off’ drug, report

Pharmaceutical companies sell some MS disease modifying therapies (DMTs) at extortionate prices. Big pharma stands accused of setting prices to rip-off the public, and the UK’s National Health Service (NHS). Who’d have thought it? I am shocked (well, no, not really). One such drug labelled a rip-off, and used to treat multiple sclerosis, is alemtuzumab. It … Continue reading MS therapy alemtuzumab is named a ‘rip-off’ drug, report

U-turn over plans to delay treatment for people who are newly-diagnosed with MS

Multiple sclerosis campaigners, led by the MS Society, are celebrating a significant victory. They opposed plans to delay access to disease modifying therapies (DMTs) for people newly diagnosed with MS in Northern Ireland. This is a UK area where certain powers, including responsibility for the National Health Service, are devolved from central government. And, the … Continue reading U-turn over plans to delay treatment for people who are newly-diagnosed with MS

Call to use MS disease modifying therapies earlier

Greater use of MRI scanning provided basis for new advice. Earlier provision of disease modifying therapies (DMTs) is now being advised for treatment of relapsing remitting multiple sclerosis. This is part of a scientific consensus that changes the way treatment should be provided in the light of evidence that suggests that, rather than waiting to … Continue reading Call to use MS disease modifying therapies earlier